Doxorubicin-mediated bone loss in breast cancer bone metastases is driven by an interplay between oxidative stress and induction of TGFβ.

PloS one

Volumn 8, Issue 10, 2013, Pages

  Rana, Tapasi ^a   Chakrabarti, Anwesa ^b   Freeman, Michael ^b   Biswas, Swati ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; DOXORUBICIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL; ARTICLE; BONE TUMOR; BREAST TUMOR; CELL DIFFERENTIATION; CELL SURVIVAL; CYTOLOGY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; METABOLISM; METASTASIS; MOUSE; OSTEOBLAST; OXIDATIVE STRESS;

ANIMALS; ANTIBODIES; BONE NEOPLASMS; BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DOXORUBICIN; FEMALE; MICE; OSTEOBLASTS; OXIDATIVE STRESS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84907042056     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078043     Document Type: Article

References (0)